½Å°æÁúȯ ½ÃÀåÁ¶»çº¸°í¼­

½Å°æÁúȯ(Neurodegenerative Disease) Ä«Å×°í¸®¿¡¼­´Â ½Å°æº¯¼º Áúȯ(´Ù¹ß¼º°æÈ­Áõ(MS), Ä¡¸Å, ¾ËÃ÷ÇÏÀ̸Ӻ´, °£Áú µî)À» Á¶»ç ´ë»óÀ¸·Î ÇÑ º¸°í¼­¸¦ ¼Ò°³ÇØ µå¸®°í ÀÖ½À´Ï´Ù. ÁßÃ߽Űæ°è ¾à¹° ÆÄÀÌÇÁ¶óÀÎ ¹× ¿¬±¸°³¹ß °ü·Ã °úÁ¦, ½ÃÀåÀÇ °¡´É¼º µî¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÑ º¸°í¼­µµ Çѵ¥ ¸ð¾Ò½À´Ï´Ù.

1 - 25 (Àüü: 563°Ç)
¼¼°èÀÇ °£Áú Ä¡·á ½ÃÀå
Epilepsy Treatment
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ µå¶óº£ ÁõÈıº ½ÃÀå
Dravet Syndrome
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¿þ¾î·¯ºí ½Å°æÀÚ±Ø ±â±â ½ÃÀå º¸°í¼­(2025³â)
Wearable Neurostimulation Devices Global Market Report 2025
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,490 £Ü 6,521,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀüÁ¤½Å°æ¿° Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Vestibular Neuronitis Treatment Global Market Report 2025
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,490 £Ü 6,521,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Àç¹ß ¿ÏÈ­Çü ´Ù¹ß¼º °æÈ­Áõ ½ÃÀå º¸°í¼­(2025³â)
Relapsing-Remitting Multiple Sclerosis Global Market Report 2025
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,490 £Ü 6,521,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æ¯¹ß¼º µÎ°³³»¾Ð Ç×ÁøÁõ Ä¡·á ½ÃÀå º¸°í¼­(2025³â)
Idiopathic Intracranial Hypertension Treatment Global Market Report 2025
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,490 £Ü 6,521,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ºÎ½Å¹éÁúÀÌ¿µ¾çÁõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Adrenoleukodystrophy Drugs Global Market Report 2025
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,490 £Ü 6,521,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÇåÆÃÅϺ´ Ä¡·á ½ÃÀå : ¾àÁ¦ À¯Çüº°(½ÂÀÎ ÀǾàǰ, ÀûÀÀ¿Ü ÀǾàǰ), À¯Åë ä³Îº°(º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹, ¼Ò¸Å ¾à±¹), Áö¿ªº° Æò°¡, ±âȸ¿Í ¿¹Ãø(2018-2032³â)
Global Huntington's Disease Treatment Market Assessment, By Drug Type [Approved Drugs, Off-Label Drugs], By Distribution Channel [Hospital Pharmacies, Online Pharmacies, Retail Pharmacies], By Region, Opportunities and Forecast, 2018-2032F
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,800 £Ü 6,971,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ½Å°æÅðÇ༺ Áúȯ ½ÃÀå : ÀûÀÀÁõº°, ¾àÁ¦ Ŭ·¡½ºº°, À¯Åë ä³Îº°, Áö¿ªº° - ±âȸ ¹× ¿¹Ãø(2018-2032³â)
Global Neurodegenerative Diseases Market Assessment, By Indication, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,800 £Ü 6,971,000 (ºÎ°¡¼¼ º°µµ)
MA(Medical Affairs) ÆòÆÇ(¹Ì±¹) - ´Ù¹ß¼º °æÈ­Áõ
Medical Affairs Reputations (US) - Multiple Sclerosis
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 8,000 £Ü 11,619,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Ä¡¸Å ¹× ¿îµ¿Àå¾Ö Ä¡·á ½ÃÀå(2025-2029³â)
Global Dementia and Movement Disorder Treatment Market 2025-2029
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 2,500 £Ü 3,631,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±Þ¼º ô¼ö ¼Õ»ó ½ÃÀå
Acute Spinal Cord Injury
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Ä¡¸Å °ü¸® Á¦Ç° ½ÃÀå ¿¹Ãø(-2032³â) : Á¦Ç°º°, À¯Åë ä³Îº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®
Dementia Care Products Market Forecasts to 2032 - Global Analysis By Product (Memory Exercise & Activity Products, Medication Management Products, Daily Reminder Products and Other Products), Distribution Channel, End User and By Geography
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 4,150 £Ü 6,027,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ºí¶óÄ«¸Þ½Å(Blarcamesine) ½ÃÀå
Blarcamesine
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±Þ¼º ±Ù±äÀåÀÌ»ó ½ÃÀå
Acute Dystonia
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸® ÁõÈıº(Leigh Syndrome) Ä¡·á ½ÃÀå
Leigh Syndrome Treatment
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¾ËÃ÷ÇÏÀ̸ÓÇü Ä¡¸Å ½ÃÀå
Dementia Associated with Alzheimer's Disease
¹ßÇà 2025³â 06¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ½Å°æ ´ë»çÀå¾Ö ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼®(À¯Çüº°, Áø´Ü ¹æ¹ýº°, Ä¡·á Á¢±Ùº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°)°ú ¿¹Ãø(2022-2032³â)
Global Neurometabolic Disorders Market Size study, by Type (Amino Acid Disorders, Organic Acidemias, Fatty Acid Oxidation Disorders, Mitochondrial Disorders), by Diagnosis Method, Therapeutic Approaches, End User and Regional Forecasts 2022-2032
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 4,950 £Ü 7,189,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±ÙÀ§Ãà¼ºÃø»ö°æÈ­Áõ ½ÃÀå : Áö¿ªº° ºÐ¼®°ú ¿¹Ãø(2025-2035³â)
Amyotrophic Lateral Sclerosis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 4,900 £Ü 7,116,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå
Anti-Epileptic Drugs for Pediatrics
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Á°ñ½Å°æÅë Ä¡·á ½ÃÀå
Sciatica Treatment
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÇÁ·¹°¡¹ß¸° ½ÃÀå
Pregabalin
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ °¨°¢ÀÌ»ó Ä¡·á ½ÃÀå
Paresthesia Treatment
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ½Å°æº´Áõ¼º ÅëÁõ ½ÃÀå
Neuropathic Pain
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ½Å°æº¯¼º Ä¡·áÁ¦ ½ÃÀå
Neurodegenerative Drugs
¹ßÇà 2025³â 05¿ù
°¡°Ý US $ 5,850 £Ü 8,496,000 (ºÎ°¡¼¼ º°µµ)
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.